PPIDT00187
Drug Information
| Name | Canakinumab |
|---|---|
| Sequence | QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB06168 |
| Type | biotech |
| Indication | Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations. In patients ≥4 years of age, canakinumab is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). In adult and pediatric patients, canakinumab is also indicated for the treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF).[L48006] Canakinumab is additionally indicated in patients ≥2 years of age for the treatment of active Still's disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA).[L48006] Canakinumab is also indicated for the treatment of gout flares in adult patients in whom standard therapies (e.g. NSAIDs, colchicine) are contraindicated, not tolerated, or ineffective, and in whom repeated courses of corticosteroids are not appropriate.[L48006] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
150 mg/ml
|
| Injection, powder, for solution | Parenteral; Subcutaneous |
150 MG
|
| Injection, powder, for solution | Subcutaneous |
150 MG
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
150 mg/1mL
|
| Injection, solution | Parenteral; Subcutaneous |
150 MG/ML
|
| Injection, solution | Subcutaneous |
150 mg
|
| Injection, solution | Subcutaneous |
150 mg/1mL
|
| Powder, for solution | Subcutaneous |
150 mg / vial
|
| Solution | Subcutaneous |
150 mg / mL
|
| Injection, solution | Subcutaneous |
150 mg/ml
|
| Injection, powder, for solution | — |
150 MG
|
| Powder, for solution | Subcutaneous |
150 mg
|
| Solution | Subcutaneous |
15000000 mg
|